Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)

Inclusion Criteria: * Age \> 19 years * Ability to give informed consent * Documented stable CAD with a significant lesion in a native coronary artery amenable to PCI with one stent * Planned single vessel intervention Exclusion Criteria: * Myocardial infarction or unstable angina within the prior 7 days * Target lesion is a chronic total occlusion (present for longer than 3 months) * Target lesion with angiographically visible thrombus or in-stent thrombosis * Target lesion is in a bypass graft * Planned use of a GP IIb/IIIa inhibitor or planned use of atherectomy including directional, rotational, or laser * Known allergies or sensitivities to heparin, pork, or pork-containing products * History of HIT * Hemodynamic instability * Stroke or Transient Ischemic Attack (TIA) in the prior 3 months * Active bleeding or bleeding diathesis * Trauma or major surgery in the preceding month or planned surgery or PCI within the 30 days after the index PCI * Suspected aortic dissection * Receiving oral anticoagulation therapy * Receipt of LMWH or of UFH (except for that used during the diagnostic portion of the index procedure) within the prior 7 days * ACT \> 200 prior to study drug administration * Severe, untreated hypertension at the time of the index PCI procedure (systolic blood pressure of \> 180 mm Hg, diastolic blood pressure \> 90 mm Hg) * Hemoglobin level of less than 10.0 g/dl or a hematocrit below 30% * Platelet count of less than 100,000 per cubic millimeter or more than 600,000 per cubic millimeter * Creatinine clearance \< 30 mL/min * Any malignancy within the prior 5 years with the exception of non-melanoma skin cancers * Prior enrollment in EMINENCE trial or currently receiving other experimental therapy * Pregnant or lactating if subject is female Substudy: Inclusion: * Ability to give informed consent * Participation in the main study protocol Exclusion: -Inability to provide the blood specimens required by the substudy protocol